home / stock / amgn / amgn quote
Last: | $269.38 |
---|---|
Change Percent: | -0.16% |
Open: | $273.45 |
Close: | $269.38 |
High: | $274.35 |
Low: | $267.24 |
Volume: | 1,760,649 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$269.38 | $273.45 | $269.38 | $274.35 | $267.24 | 1,760,649 | 04-25-2024 |
$273.01 | $270.63 | $273.01 | $274.858 | $269.645 | 2,458,976 | 04-24-2024 |
$273.54 | $272.14 | $273.54 | $274.48 | $271.05 | 2,492,542 | 04-23-2024 |
$271.91 | $269.84 | $271.91 | $273.14 | $269.84 | 2,165,755 | 04-22-2024 |
$268.93 | $264.63 | $268.93 | $269.38 | $260.68 | 3,380,330 | 04-19-2024 |
$262.75 | $265.64 | $262.75 | $265.92 | $262.58 | 2,082,791 | 04-18-2024 |
$264.07 | $267.54 | $264.07 | $268.775 | $263.385 | 2,175,120 | 04-17-2024 |
$265.64 | $266.83 | $265.64 | $267.51 | $263.81 | 2,017,573 | 04-16-2024 |
$265.51 | $269.93 | $265.51 | $270.9289 | $264.345 | 1,740,174 | 04-15-2024 |
$267.28 | $268.77 | $267.28 | $269.3 | $266.165 | 2,140,134 | 04-12-2024 |
$270 | $270.22 | $270 | $273 | $268.445 | 2,169,844 | 04-11-2024 |
$266.45 | $267.96 | $266.45 | $268.38 | $264.63 | 1,949,622 | 04-10-2024 |
$270.36 | $270.19 | $270.36 | $271.29 | $268.575 | 1,792,627 | 04-09-2024 |
$269.2 | $269.48 | $269.2 | $270.21 | $267.555 | 1,830,835 | 04-08-2024 |
$269.95 | $265.9 | $269.95 | $273.07 | $265.08 | 2,293,985 | 04-05-2024 |
$268.09 | $276.05 | $268.09 | $276.7299 | $267.7509 | 2,451,166 | 04-04-2024 |
$274.42 | $275.69 | $274.42 | $276.47 | $273.68 | 1,669,239 | 04-03-2024 |
$276.21 | $283.34 | $276.21 | $283.91 | $276.04 | 2,220,528 | 04-02-2024 |
$283.04 | $282.11 | $283.04 | $283.83 | $279 | 1,868,570 | 04-01-2024 |
$284.32 | $287.86 | $284.32 | $288.565 | $284.21 | 2,289,919 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3x...
2024-04-18 05:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in...